Following combination therapy, the authors observed reduced tumor growth and increased apoptosis along with decreased expression of wild-type FLT3, p65, and NF-κB regulated genes such as cyclin D1 and BCL-2, suggesting the potential use of these inhibitors for treating AML [156]. Here, BCL2 is linked to acute myeloid leukemia.